NM_000527.5(LDLR):c.223T>G (p.Cys75Gly) AND Familial hypercholesterolemia

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Apr 5, 2022
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV002952889.3

Allele description [Variation Report for NM_000527.5(LDLR):c.223T>G (p.Cys75Gly)]

NM_000527.5(LDLR):c.223T>G (p.Cys75Gly)

Gene:

LDLR:low density lipoprotein receptor [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

19p13.2

Genomic location:

Preferred name:

NM_000527.5(LDLR):c.223T>G (p.Cys75Gly)

HGVS:

NC_000019.10:g.11102696T>G
NG_009060.1:g.18316T>G
NG_140409.1:g.591T>G
NM_000527.5:c.223T>GMANE SELECT
NM_001195798.2:c.223T>G
NM_001195799.2:c.190+2351T>G
NM_001195800.2:c.223T>G
NM_001195803.2:c.223T>G
NM_001406861.1:c.481T>G
NP_000518.1:p.Cys75Gly
NP_000518.1:p.Cys75Gly
NP_001182727.1:p.Cys75Gly
NP_001182729.1:p.Cys75Gly
NP_001182732.1:p.Cys75Gly
NP_001393790.1:p.Cys161Gly
LRG_274t1:c.223T>G
LRG_274:g.18316T>G
LRG_274p1:p.Cys75Gly
NC_000019.9:g.11213372T>G
NM_000527.4:c.223T>G

Protein change:

C161G

Molecular consequence:

NM_001195799.2:c.190+2351T>G - intron variant - [Sequence Ontology: SO:0001627]
NM_000527.5:c.223T>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001195798.2:c.223T>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001195800.2:c.223T>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001195803.2:c.223T>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001406861.1:c.481T>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Familial hypercholesterolemia
Identifiers:: MONDO: MONDO:0005439; MedGen: C0020445; OMIM: PS143890

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV003273240	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (Apr 5, 2022)	germline	clinical testing	PubMed (6) [See all records that cite these PMIDs] 10089940, 7548065, 7603991, 7979249, 18325082, 28492532

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV003273240

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(Apr 5, 2022)

germline

clinical testing

PubMed (6)
[See all records that cite these PMIDs]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Familial hypercholesterolemia kindred in Utah with novel C54S mutations of the LDL receptor gene.

Emi M, Yamaki E, Hirayama T, Katsumata H, Pozharov V, Wu LL, Hopkins PN, Williams RR.

Jpn Heart J. 1998 Nov;39(6):785-9.

PubMed [citation]

PMID:: 10089940

Disulfide bridges of a cysteine-rich repeat of the LDL receptor ligand-binding domain.

Bieri S, Djordjevic JT, Daly NL, Smith R, Kroon PA.

Biochemistry. 1995 Oct 10;34(40):13059-65.

PubMed [citation]

PMID:: 7548065

See all PubMed Citations (6)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV003273240.2

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (6)

Description

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant disrupts the p.Cys75 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10089940; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. This variant affects a cysteine residue located within an LDLRA or epidermal-growth-factor (EGF)-like domains of the LDLR protein. Cysteine residues in these domains have been shown to be involved in the formation of disulfide bridges, which are critical for protein structure and stability (PMID: 7548065, 7603991, 7979249). In addition, missense substitutions within the LDLRA and EGF-like domains affecting cysteine residues are overrepresented among patients with hypercholesterolemia (PMID: 18325082). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This missense change has been observed in individual(s) with clinical features of hypercholesterolemia (Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces cysteine, which is neutral and slightly polar, with glycine, which is neutral and non-polar, at codon 75 of the LDLR protein (p.Cys75Gly).

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine